These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27292781)

  • 21. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
    Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
    Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
    Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating anticoagulation sensitivity among elderly patients managed with an institution's heparin protocol using initial anti-factor Xa levels.
    Lemke A; Kohs J; Weber L
    Am J Health Syst Pharm; 2020 Feb; 77(Supplement_1):S13-S18. PubMed ID: 31985745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis.
    Kapoor A; Ellis A; Shaffer N; Gurwitz J; Chandramohan A; Saulino J; Ishak A; Okubanjo T; Michota F; Hylek E; Trikalinos TA
    J Thromb Haemost; 2017 Feb; 15(2):284-294. PubMed ID: 28102615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
    Shirley M; Dhillon S
    Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule coagulation cascade inhibitors in the clinic.
    Saiah E; Soares C
    Curr Top Med Chem; 2005; 5(16):1677-95. PubMed ID: 16375748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism.
    Brenner B; Hoffman R
    Blood Rev; 2011 Sep; 25(5):215-21. PubMed ID: 21605928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
    J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective management of acute deep vein thrombosis: direct oral anticoagulants.
    Roussin A
    Int Angiol; 2015 Feb; 34(1):16-29. PubMed ID: 24927023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of novel oral anticoagulants.
    Abo-Salem E; Becker RC
    Curr Opin Pharmacol; 2016 Apr; 27():86-91. PubMed ID: 26939028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pros and cons of new oral anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors.
    Ahrens I; Bode C
    Curr Drug Discov Technol; 2012 Jun; 9(2):129-36. PubMed ID: 21838659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
    Apostolakis S; Lip GY
    Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.